论文部分内容阅读
目的分析靶动脉灌注维拉帕米联合化疗药物介入治疗晚期肺癌的临床疗效。方法对我院收治的48例晚期肺癌患者实施靶动脉灌注维拉帕米联合化疗药物介入治疗,观察治疗后血常规、毒副作用、心功能及心电图变化情况,并进行临床疗效评价。结果治疗2个月后总有效率为100%。48例患者均发生不同程度血常规异常及毒副作用,治疗前后患者心功能无变化,心电图结果显示维拉帕米灌注前、灌注中、灌注后5 min心率、血压无变化。结论靶动脉灌注维拉帕米联合化疗药物介入治疗晚期肺癌能够有效提高化疗效果,能够缩小病灶,降低患者临床分期,疗效显著,临床应用价值较高。
Objective To analyze the clinical efficacy of percutaneous verapamil combined with chemotherapy in the treatment of advanced lung cancer. Methods 48 patients with advanced lung cancer admitted to our hospital were treated with percutaneous verapamil combined with chemotherapy. The changes of blood routine, toxic and side effects, heart function and electrocardiogram were observed after treatment. Clinical efficacy evaluation was performed. Results The total effective rate after 2 months of treatment was 100%. All 48 patients had abnormal blood routine abnormalities and toxic and side effects. There was no change in heart function before and after treatment. ECG results showed that there was no change in heart rate and blood pressure before, during, and after 5 minutes of verapamil. Conclusion Infusion of verapamil combined with chemotherapy for target artery perfusion for advanced lung cancer can effectively improve the effect of chemotherapy, can reduce the lesion, reduce the clinical stage of the patient, has significant curative effect, and has higher clinical application value.